ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...
21h
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging ...
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) submitted and on track for potential FDA approval 2H 2025; strategic partnership with Nippon Shinyaku aims to expand ...
Here is how the Barron’s Roundtable members’ picks performed. Find investment ideas for your portfolio with the latest stock picks from Barron’s below. These picks are the product of the ...
The drug is therapeutically equivalent to Novartis' Votrient... ICAI to Review IndusInd Bank Financials Amid Accounting Discrepancies The ICAI may review IndusInd Bank's financial statements after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback